PRVB News and Press, Provention Bio Inc. From 11/03/21

Provention Bio (NASDAQ:PRVB) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.52 and the consensus Revenue Estimate is $1.25M Over the last 3 months, EPS estimates have seen 4 upward revisions and 0 downward. Revenue...

Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021 PR Newswire RED BANK, N.J. , Oct. 28, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated ...

Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Positive data supp...

Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 PR Newswire RED BANK, N.J. , Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immu...

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit PR Newswire RED BANK, N.J. , Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventin...

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy Company working with the U.S. FDA to fin...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the term “technology” often brings to mind the broader digitalization movement, tech actually has the most potential in healthcare. Thanks to groundbreaking innovations, we now know much more about the h...

Image source: The Motley Fool. Provention Bio, inc (NASDAQ: PRVB) Q2 2021 Earnings Call Aug 6, 2021 , 10:00 p.m. ET Operator Continue reading For further details see: Provention Bio, inc (PRVB) Q2 2021 Earnings Call Transcript

The following slide deck was published by Provention Bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Provention Bio, Inc. 2021 Q2 - Results - Earnings Call Presentation

Provention Bio (NASDAQ:PRVB): Q2 GAAP EPS of -$0.46 beats by $0.06. Cash and cash equivalents and marketable securities of $176.4 million. Press Release For further details see: Provention Bio EPS beats by $0.06